Epic Sciences

About Epic Sciences

Epic Sciences is a company focused on unlocking answers from cells through innovative tests to extend lives. They specialize in cancer research and diagnostics, offering solutions that empower patients and doctors to choose effective precision therapies.

Products & Services

AR-V7 Test:A CTC-based liquid-biopsy test for men with metastatic castration-resistant prostate cancer (mCRPC). It is Medicare reimbursed, clinically validated, and requires only a simple blood draw to help choose effective therapies.

DefineMBC:A product mentioned in the navigation, likely related to cancer diagnostics or research, though specific details are not provided in the content.

Biopharma Solutions:A program for pharmaceutical and clinical investigation partners, offering a bias-free approach for cancer research, enhancing drug development, and providing insights into cancer growth and evolution.

Specialties

Cancer Diagnostics Liquid Biopsy Circulating Tumor Cells (CTC) Precision Therapies Drug Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series G T: - FT: Series G	A: 24000000 MR: - FA: 24 million FAN: 24000000	D: 2023-04-14 FD: 2023-04-14	5 investors

Series G Latest

2023-04-14

$24.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News

Epic Sciences Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised